期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 231, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.114145
关键词
Thiophene-benzenesulfonamide; Drug-resistant tuberculosis; SAR exploration; Druggability evaluation
资金
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2018PT35026]
- CAMS Innovation Fund for Medical Sciences [CAMS-2016-I2M-1-010]
A series of thiophene-benzenesulfonamide derivatives were designed and synthesized to explore their structure-activity relationship as antituberculosis agents. Compound 17b showed improved activity compared to the lead compounds, displaying good intracellular antimycobacterial activity and favorable drug properties.
A series of thiophene-benzenesulfonamide derivatives was designed and synthesized by exploring the structure-activity relationship of lead compounds 2,3-disubstituted thiophenes 25a and 297F as antituberculosis agents, which displayed potent antimycobacterial activity against drug-susceptible and clinically isolated drug-resistant tuberculosis. In particular, compound 17b, which had improved activity (minimum inhibitory concentration of 0.023 mu g/mL) compared with the lead compounds, displayed good intracellular antimycobacterial activity in macrophages with a reduction of 1.29 log(10) CFU. A druggability evaluation indicated that compound 17b had favorable hepatocyte stability, low cytotoxicity, and low hERG channel inhibition. Moreover, compound 17b exhibited modest in vivo efficacy in an acute mouse model of tuberculosis. In addition, the molecular docking study elucidated the binding mode of compound 17b in the active site of DprE1. Therefore, compound 17b may be a promising antituberculosis lead for further research.& nbsp;(c) 2022 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据